Evolucion en la prescripcion de farmacos antiulcerosos en Espana durante los anos 1995 al 1998

• Autores: Mª José Montero Fernández
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 2, Nº. 4, 2000, págs. 351-357
• Idioma: español
• Títulos paralelos:
  • Evolution in the prescription of anti-ulcerous drugs in Spain during the years 1995 to 1998
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To describe the evolution in the consumption of anti-ulcerous drugs by active principle in containers and import. Desing: Retrospective observational transversal study. Placement: Consumption of prescribed containers in Spain during the years 1995 to 1998 at the level of anti-ulcerous active principles. Measurements and results: The measures used are the percent in the consumption of DDD, the DHD (daily doses defined for 1000 inhabitants and day) and DTC (Daily Treatment Cost). The consumption of anti-ulcerous drugs has increased over these four years, with special incidence in the omeprazol. The antagonists to the Histamine 2 have increased, though to a lesser extent. In regard to the cost, the treatment cost per day has clearly decreased, above all in the omeprazol and the ranitidine. The rest of the drugs tend to the lowering in their consumption, except the drugs of recent commercialization like the lansoprazol, the pantoprazol, the roxatidine and the bismuth ranitidine. Conclusions: The consumption of these drugs is higher every year, and above all the case of the omeprazol, which displaces the ranitidine from the first place that this last one occupied in the year 1995. The consuption in DDD of these two medications in 95' is 34.35% and 39.08% respectively and in 98' 44.96% and 31.49%. The DTC is higher in the proton-pump inhibitors, although the cost of the omeprazol decreased over these four years. The ranitidine DTC decreased in 98' thanks to the appearance of the generics EFG in 1997. On a global level, the prescription of these drugs is very high; being of 82 million containers and 272, 558 million pesetas during these four years. But, above all, we must inquire if the use has been the right one and if the investment has been the adequate one. Discovered one of the major causes of the prevalence of the disease, the Helicobacter pylori,2,3 it should imply a greater rate of healing and a decrease in the recurrences, thus, diminishing the consumption of these drugs